share_log

8-K: ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

8-K: ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

8-K:ENDRA 生命科学公布2024年第三季度财务业绩并提供业务最新情况
美股SEC公告 ·  2024/11/16 05:10

Moomoo AI 已提取核心信息

ENDRA Life Sciences reported Q3 2024 financial results and provided a business update. The company accelerated enrollment in its global multisite pilot study, with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA also developed new AI-based data analysis features for its TAEUS platform and activated a system at LMU University Hospital in Germany for a post-market study.Operating expenses decreased 52% YoY to $1.5 million in Q3 2024. Net loss was $2.4 million, including a $911,000 non-cash charge related to warrants. Cash and equivalents stood at $4.7 million as of September 30, 2024. The company implemented cost-cutting measures, realizing $3.1 million in annualized savings and reducing Q3 expenses by 54% YoY.ENDRA is focusing on securing clinical data to support a new De Novo regulatory filing with the FDA for its TAEUS liver device. The company expanded its patent portfolio to 82 issued patents globally and plans to hold periodic business update calls for shareholders going forward.
ENDRA Life Sciences reported Q3 2024 financial results and provided a business update. The company accelerated enrollment in its global multisite pilot study, with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA also developed new AI-based data analysis features for its TAEUS platform and activated a system at LMU University Hospital in Germany for a post-market study.Operating expenses decreased 52% YoY to $1.5 million in Q3 2024. Net loss was $2.4 million, including a $911,000 non-cash charge related to warrants. Cash and equivalents stood at $4.7 million as of September 30, 2024. The company implemented cost-cutting measures, realizing $3.1 million in annualized savings and reducing Q3 expenses by 54% YoY.ENDRA is focusing on securing clinical data to support a new De Novo regulatory filing with the FDA for its TAEUS liver device. The company expanded its patent portfolio to 82 issued patents globally and plans to hold periodic business update calls for shareholders going forward.
ENDRA Life Sciences公布了2024年第三季度财务结果,并提供了业务更新。该公司加快了全球多中心试点研究的招生,在过去两个月中,有近40名受试者被登记或正在扫描。ENDRA还为其TAEUS平台开发了新的人工智能数据分析功能,并在德国LMU大学医院启用了一个用于市场后研究的系统。营业费用同比减少52%,降至150万美元。净亏损为240万美元,包含至909,000美元的与Warrants相关的非现金费用。截止2024年9月30日,现金及现金等价物为470万美元。公司实施了削减成本的措施,实现了310万美元的年度节省,并使第三季度的费用同比减少54%。ENDRA专注于获取临床数据,以支持其TAEUS肝脏设备向FDA提交新的De Novo监管申请。该公司将其全球专利组合扩展到82项已授予的专利,并计划定期召开业务更新电话会议,以便与股东进行交流。
ENDRA Life Sciences公布了2024年第三季度财务结果,并提供了业务更新。该公司加快了全球多中心试点研究的招生,在过去两个月中,有近40名受试者被登记或正在扫描。ENDRA还为其TAEUS平台开发了新的人工智能数据分析功能,并在德国LMU大学医院启用了一个用于市场后研究的系统。营业费用同比减少52%,降至150万美元。净亏损为240万美元,包含至909,000美元的与Warrants相关的非现金费用。截止2024年9月30日,现金及现金等价物为470万美元。公司实施了削减成本的措施,实现了310万美元的年度节省,并使第三季度的费用同比减少54%。ENDRA专注于获取临床数据,以支持其TAEUS肝脏设备向FDA提交新的De Novo监管申请。该公司将其全球专利组合扩展到82项已授予的专利,并计划定期召开业务更新电话会议,以便与股东进行交流。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息